Peter Pack

Keine laufenden Positionen mehr

61 Jahre

Health Technology

Consumer Services

Finance

Profil

Peter Pack was the founder of mtm laboratories AG, founded in 1999, and served as Chief Executive Officer in 2008.
Former jobs include Chief Executive Officer & Director at Crescendo Biologics Ltd. from 2015 to 2019, Non-Executive Chairman at Oxford BioDynamics Plc in 2020, Director-Research & Development at MorphoSys AG, Director at Sartorius Polyplus SAS, Managing Director at Polytech Domilens GmbH, and Partner at EMBL Ventures GmbH.
Education history includes an undergraduate degree from the University of Münster in 1990 and a doctorate from Ludwig-Maximilians-Universität München in 1994.

Ehemalige bekannte Positionen von Peter Pack

Unternehmen	Position	Ende
OXFORD BIODYNAMICS PLC	Vorsitzender	14.12.2020
Crescendo Biologics Ltd. Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in the development of new medicines based on antibody fragment technology	Vorstandsvorsitzender	01.05.2019
mtm laboratories AG mtm laboratories AG Medical SpecialtiesHealth Technology Develops and manufactures diagnostic and detection products for cervical cancer	Gründer	14.11.2008
EMBL Ventures GmbH EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures is a hands-on, long-term manager which invests in disruptive biology and life-science related products and technologies with global potential, including therapeutics, target validation and drug design, technology platforms, medical devices and diagnostics developed at the EMBL, from EMBL alumni and from non-EMBL third parties. The firm seeks to invest in entrepreneurial management teams with: a combination of relevant technical expertise, drive, business sense and a down-to-earth attitude; ownership of a proprietary core or platform technology generating a proprietary position or clear competitive advantage in a defined market sector and a solution for a problem with a significant advantage in a market of substantial size and the chance to achieve a leading, sustainable market position. EMBL Ventures typically acts as the lead or co-lead investor for initial financing and also participates in follow-up financing. They partner with their investee companies, taking a seat on the board of directors. To maximize the intrinsic value of a technology or product, the firm's investment strategy targets one of the main value inflection points, typically the transition from early development or conceptual stage up to proof of concept.	Private Equity Investor	-
Polyplus-transfection SA Polyplus-transfection SA BiotechnologyHealth Technology Provides cell and gene therapy services	Direktor/Vorstandsmitglied	-

Sehen Sie sich die Erfahrung von Peter Pack im Detail an

Ausbildung von Peter Pack

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Peter Pack im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	9
MorphoSys AG MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services	Health Technology
mtm laboratories AG mtm laboratories AG Medical SpecialtiesHealth Technology Develops and manufactures diagnostic and detection products for cervical cancer	Health Technology
EMBL Ventures GmbH EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures is a hands-on, long-term manager which invests in disruptive biology and life-science related products and technologies with global potential, including therapeutics, target validation and drug design, technology platforms, medical devices and diagnostics developed at the EMBL, from EMBL alumni and from non-EMBL third parties. The firm seeks to invest in entrepreneurial management teams with: a combination of relevant technical expertise, drive, business sense and a down-to-earth attitude; ownership of a proprietary core or platform technology generating a proprietary position or clear competitive advantage in a defined market sector and a solution for a problem with a significant advantage in a market of substantial size and the chance to achieve a leading, sustainable market position. EMBL Ventures typically acts as the lead or co-lead investor for initial financing and also participates in follow-up financing. They partner with their investee companies, taking a seat on the board of directors. To maximize the intrinsic value of a technology or product, the firm's investment strategy targets one of the main value inflection points, typically the transition from early development or conceptual stage up to proof of concept.	Finance
University of Münster University of Münster Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Ludwig-Maximilians-Universität München Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Polyplus-transfection SA Polyplus-transfection SA BiotechnologyHealth Technology Provides cell and gene therapy services	Health Technology
Crescendo Biologics Ltd. Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in the development of new medicines based on antibody fragment technology	Commercial Services
Polytech Domilens GmbH Polytech Domilens GmbH Electronic ComponentsElectronic Technology Provides research and development services related to ophthalmology	Electronic Technology
Oxford BioDynamics Plc Oxford BioDynamics Plc BiotechnologyHealth Technology Discovers and develops novel biomarkers	Health Technology